A New Drug for ALS?
Merit Cudkowicz, MD, of Harvard Medical School, discusses the results of a phase 2 study—a reduction in functional decline and a significant drop in the death rate in those on the highest dose of the drug, dexpramipexole. See the Dec. 15 issue of Neurology Today for the full-text article: http://bit.ly/uqFbG7.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Neurology Now Podcast?
This episode is 6 minutes long.
When was this Neurology Now Podcast episode published?
This episode was published on December 21, 2011.
Can I download this Neurology Now Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.